用莫加莫拉单抗单药成功治疗CCR4+掌跖蕈样肉芽肿 - Suppr

Successful treatment of CCR4+ mycosis fungoides palmaris et plantaris with mogamulizumab monotherapy.

作者信息

Fujimura Taku, Kambayashi Yumi, Ohuchi Kentaro, Amagai Ryo, Muto Yusuke, Aiba Setsuya

机构信息

Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

出版信息

Dermatol Ther. 2020 Jul;33(4):e13731. doi: 10.1111/dth.13731. Epub 2020 Jun 29.

DOI:10.1111/dth.13731

PMID:32474985

Abstract

摘要

相似文献

Successful treatment of CCR4+ mycosis fungoides palmaris et plantaris with mogamulizumab monotherapy.

Dermatol Ther. 2020 Jul;33(4):e13731. doi: 10.1111/dth.13731. Epub 2020 Jun 29.

Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab.

Dermatol Ther. 2020 Nov;33(6):e14099. doi: 10.1111/dth.14099. Epub 2020 Aug 17.

Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.

Clin Cancer Res. 2015 Jan 15;21(2):274-85. doi: 10.1158/1078-0432.CCR-14-0830. Epub 2014 Nov 5.

Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.

Clin Lymphoma Myeloma Leuk. 2021 Feb;21(2):97-105. doi: 10.1016/j.clml.2020.09.003. Epub 2020 Sep 18.

Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.

Drug Des Devel Ther. 2020 Sep 16;14:3747-3754. doi: 10.2147/DDDT.S185896. eCollection 2020.

FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.

Clin Cancer Res. 2019 Dec 15;25(24):7275-7280. doi: 10.1158/1078-0432.CCR-19-2030. Epub 2019 Jul 31.

Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment.

Dermatol Ther. 2020 Jul;33(4):e13487. doi: 10.1111/dth.13487. Epub 2020 May 22.

Successful treatment of relapsed folliculotropic mycosis fungoides with mogamulizumab followed by intensity-modulated radiotherapy.

J Dermatol. 2018 Apr;45(4):e84-e85. doi: 10.1111/1346-8138.14111. Epub 2017 Oct 25.

Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.

Blood. 2022 Jun 30;139(26):3732-3736. doi: 10.1182/blood.2021014468.

Efficacy of Oral Alitretinoin in Treatment of Mycosis Fungoides Palmaris et Plantaris.

Acta Derm Venereol. 2023 Dec 13;103:adv18472. doi: 10.2340/actadv.v103.18472.

引用本文的文献

Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.

Int J Mol Sci. 2024 Feb 12;25(4):2203. doi: 10.3390/ijms25042203.

Clinical characteristics of Mycosis fungoides palmaris et plantaris: two cases and a systematic literature review.

Eur J Dermatol. 2022 May 1;32(3):421-423. doi: 10.1684/ejd.2021.4126.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Successful treatment of CCR4+ mycosis fungoides palmaris et plantaris with mogamulizumab monotherapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Successful treatment of CCR4+ mycosis fungoides palmaris et plantaris with mogamulizumab monotherapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献